The Bangalore based Sami Labs, a major producer and
exporter of standardised herbal extracts, fine chemicals and nutraceuticals is scouting
for new markets in the overseas for its products under the herbal extracts division. The
two new markets the company is eyeing at present are South America and Japan.
A totally integrated national pharma company and a world leader in
standardised extracts, Sami Labs plans to fortify its herbal extracts division in the
overseas market. The company also plans to launch two or three new products under its
formulations division by the end of the month.
The division focussed on domestic market currently has eight products
and has another eight products in pipeline. With market presence in Tamilnadu, Kerala,
Maharashtra, Karnataka and Andhra Pradesh, the company will shortly enter Madhya Pradesh
and by the end of the year plans to put national distribution in place.
Sami Labs has developed a new and cost effective process for African
sleeping sickness. Two other molecules - one anti inflammatory and another for
prostate care prevention are undergoing preclinical trials, informed Dr
Muhammed Majeed, the managing director. We are looking at cardiovascular and
diabetes at new areas of research, he added.
The companys expansion plans include setting up a major solid
dosage forms facility for manufacturing nutraceuticals, cosmoceuticals and other dosage
forms at its premises. The state-of-the-art facility estimated at Rs 68 crores will meet
all overseas regulatory body approvals and be completed in another one year.
We are planing collaborative efforts with overseas
companies for newer products and newer ideas in biotechnology. We have identified the
partners and are in talks with them, says Dr Majeed.
With a continued thrust on exports, Sami Labs aims to become Rs 300
crore company in the next two or three years. This year our focus is on
national level marketing, Dr Majeed reveals.
The company which posted Rs 70 crore revenues this year has filed 10